Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Pipeline Developments & Deals by Umecrine Cognition

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Umecrine Cognition

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Karolinska Development’s Portfolio Company Umecrine Cognition Presents Data from Clinical Phase 2a Study at AALSD International Liver Meet...

              Contact the Supplier

              Lead Product(s): Golexanolone

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GR3027

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 02, 2020

              Details:

              Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy.

              Umecrine Cognition

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SWEDEN Sweden

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Karolinska Development’s Portfolio Company Umecrine Cognition Presents Positive Additional Results From A Phase 2a Study Of Golexanolone

              Contact the Supplier

              Lead Product(s): Golexanolone

              Therapeutic Area: Sleep Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 08, 2020

              Details:

              Analyses of data for additional efficacy endpoints reveal that treatment with the golexanolone exerts a significant effect on brain signaling with a positive effect on excessive daytime sleepiness.

              PharmaCompass__DigitalAd